Previous studies have highlighted the potential health effects of phthalate exposure, such as atopic dermatitis and asthma. However, evidence supporting the association between phthalate exposure and atopic dermatitis is limited and based on data collected from Western populations. This study aimed to analyze the association between phthalate exposure and atopic dermatitis in Korean adolescents aged 12-17 years using a nationally representative dataset. We conducted a cross-sectional study using a publicly available dataset from the third Korean National Environmental Health Survey ( = 797). We divided the study participants into four quartiles according to urinary phthalate metabolite concentrations. The odds ratio of having atopic dermatitis was calculated using the first quartile as the reference group in binary logistic regression. We found that in the logistic regression model, both the urinary Mono-(2-ethyl-5-carboxypentyl) phthalate (MECCP; OR: 1.81; CI: 1.01-3.25) and Mono-benzyl phthalate (MBzP; OR: 1.81; CI: 1.01-3.25) concentrations in the highest quartile were positively associated with atopic dermatitis. The atopic dermatitis group had a significantly higher mean urinary MECCP and MBzP concentration. In the future, longitudinal studies involving repeated measurements are warranted to analyze the long-term effects of phthalate.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956342 | PMC |
http://dx.doi.org/10.3390/ijerph18052261 | DOI Listing |
Expert Opin Drug Saf
December 2024
Department of Dermatology, IDI-IRCCS, Dermatological Research Hospital, Rome, Italy.
J Invest Dermatol
December 2024
Department of Medicine and Women's College Research and Innovation Institute, Women's College Hospital, Toronto, Canada; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada. Electronic address:
Expert Opin Drug Saf
December 2024
Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.
Background: Ruxolitinib cream, a topical Janus kinase (JAK) inhibitor, is a widely used treatment for various dermatological diseases. This study employs the FDA Adverse Event Reporting System (FAERS) database to examine adverse events (AEs) associated with ruxolitinib cream.
Methods: This study employed disproportionate analysis methods, including reported odds ratio and proportional reporting ratio, to collate AEs reported from the fourth quarter of 2021 to the first quarter of 2024.
J Dermatol
December 2024
Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
This is the English version of the 2024 clinical practice guidelines for the management of atopic dermatitis (AD). AD is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus.
View Article and Find Full Text PDFEur J Pediatr
December 2024
Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Box 424, 405 30, Gothenburg, Sweden.
Unlabelled: Atopic dermatitis, food allergy, allergic rhinitis, and asthma are among the most common diseases in childhood. They are heterogeneous diseases, can co-exist in their development, and manifest complex associations with other disorders and environmental and hereditary factors. Elucidating these intricacies by identifying clinically distinguishable groups and actionable risk factors will allow for better understanding of the diseases, which will enhance clinical management and benefit society and affected individuals and families.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!